| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25778d19f5e786210ff0acdaea90a600 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 |
| filingDate |
2015-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69309417f212916350688f1a4557af1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_587ab14383b188e7afa08bf045967850
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_584c1c524379b20d3fe94d2cc6d13dc7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ceb151536dce61bec4c4ac57a1c73ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2832de3fe3e652fcc84318a0e0c09349 |
| publicationDate |
2020-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2727204-C2 |
| titleOfInvention |
Method of producing phenylephrine resinate particles, phenylephrine resinate particles and using phenylephrine resinate particles in pharmaceutical compositions |
| abstract |
FIELD: pharmaceutical industry. n SUBSTANCE: group of inventions refers to a pharmaceutical complex drug—resin. Pharmaceutical complex drug—resin containing phenylephrine and sodium polystyrene sulphonate, wherein the particle size of said sodium polystyrene sulphonate before combining with phenylephrine ranges from 74 mcm to 177 mcm, and the drug—resin complex contains phenylephrine and the resin at ratio of 1.25:1 to 1.6:1. Delayed release particle for phenylephrine delivery. Pharmaceutical composition containing sustained release particle. A method for forming a drug-resin complex with a coating. n EFFECT: above-described solution group enables to obtain a drug with prolonged release. n 19 cl, 16 tbl, 8 dwg, 14 ex |
| priorityDate |
2014-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |